钠-葡萄糖耦联转运体2抑制剂的药物基因组学研究进展  

Study progress on pharmacogenomics of sodium-glucose linked transporter 2 inhibitors

作　　者：庄永如 宋金方 ZHUANG Yongru;SONG Jinfang(Dept.of Pharmacy,the Affiliated Hospital of Jiangnan University,Jiangsu Wuxi 214000,China;School of Pharmacy,Xuzhou Medical University,Jiangsu Xuzhou 221000,China)

机构地区：[1]江南大学附属医院药学部,江苏无锡214000 [2]徐州医科大学药学院,江苏徐州221000

出　　处：《中国药房》2024年第14期1790-1794,共5页China Pharmacy

基　　金：国家自然科学基金项目(No.82204536);无锡市第二届“双百”中青年医疗卫生拔尖人才计划(No.HB2023064)。

摘　　要：钠-葡萄糖耦联转运体2抑制剂(SGLT2i)是一类新型口服降糖药物,广泛应用于2型糖尿病患者的降糖治疗,但由于患者的遗传背景差异,常导致药物治疗的反应性多样。本文通过综述SGLT2i的药物基因组学研究报道,发现UGT1A9、UGT2B4、SLC5A2、ABCB1、PNPLA3、WFS1基因变异可能影响SGLT2i的药代动力学以及SGLT2i在改善非酒精性脂肪性肝病、减重等方面的降糖外效应,但尚无足够的临床证据支持基因多态性影响SGLT2i的降糖疗效。Sodium-glucose linked transporter 2 inhibitors(SGLT2i) are novel oral hypoglycaemic agents and are widely used for hypoglycemic therapy in patients with type 2 diabetes mellitus,but differences in the genetic backgrounds of patients often lead to variable responsiveness to drug therapy.By summarizing the pharmacogenomic studies of SGLT2i,the article found that the genetic variants of UGT1A9,UGT2B4,SLC5A2,ABCB1,PNPLA3 and WFS1 may influence the pharmacokinetics of SGLT2i and the external hypoglycemic effects of SGLT2i in improving non-alcoholic fatty liver disease,weight loss and so on,but there is no clinical evidence that genetic polymorphisms affect the hypoglycemic efficacy of SGLT2i.

关 键 词：基因多态性 钠-葡萄糖耦联转运体2抑制剂 个体差异 药物基因组学 药代动力学 药效动力学 

分 类 号：R977.15[医药卫生—药品] R968[医药卫生—药学]